You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

404 Results
Drug
Other Name(s): Firmagon®
Feb 2025
Drug
Other Name(s): Cosmegen®
Jan 2022
Drug
Jun 2025
Drug
Other Name(s): Ifex® (multiple brands available)
Aug 2016
Drug
Other Name(s): Xgeva®; Wyost™
Oct 2024
Drug
Other Name(s): Yervoy®
Aug 2024
Drug
Other Name(s): Tafinlar®
Jun 2025
Drug
Other Name(s): Zydelig™
Feb 2022
Drug
Other Name(s): Darzalex®
Jan 2023
Drug
Other Name(s): Ninlaro™
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Intent: Palliative
Jun 2025

Pages